Farletuzumab ecteribulin, CAS 2407465-18-1

Product Description: Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Keiji Furuuchi, et al. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models. Cancer Sci. 2021 Jun;112(6):2467-2480./[2]Xin Cheng, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675.

CAS Number: 2407465-18-1

Molecular Weight: 149000 (average)

Compound Purity: 97.87

Research Area: Cancer

Solubility: H2O

Target: Antibody-Drug Conjugates (ADCs)

• Artikelnummer: MEXHY-P99612-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99612-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK